New advancements in cystic fibrosis medical research have been welcomed by the Cystic Fibrosis Trust as it stands to benefit up to half of all people living with cystic fibrosis (CF) in the UK.
The results of a phase III trial for a new treatment for people with cystic fibrosis aged 12 and over with two copies of the F508del mutation released by Vertex Pharmaceuticals, demonstrate that a combination of the drugs ivacaftor and lumacaftor could offer this group of people additional treatment to address the underlying cause of the disease and increase lung capacity.
Vertex has announced that it will apply for licences to market this treatment in the US and EU later this year.
